Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16649809 | 1.00 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL5463468 | 1.00 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL16649546 | 0.87 | SLC6A2 (0.53) | SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL27940516 | 0.84 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL12498003 | 0.84 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL5455487 | 0.81 | OPRM1 (0.38) | SLC6A4SLC6A2SLC6A3SCN4A | |
| SCHEMBL5456889 | 0.81 | OPRM1 (0.38) | SLC6A4SLC6A2SLC6A3SCN4A | |
| SCHEMBL20811251 | 0.81 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL16649787 | 0.81 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL17176032 | 0.80 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420679-B2 | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | SANOFI-AVENTIS (FR) | 2007-12-06 | — | — | US | disclosed |
| CN-1167692-C | Aminothiazole derivatives and their use as CRF receptor ligands | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-09-22 | — | — | CN | disclosed |
| EP-1200419-B1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI SYNTHELABO (FR) | 2004-04-14 | — | — | EP | disclosed |
| US-6586456-B1 | Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide | SANOFI-SYNTHELABO (FR) | 2003-07-01 | — | — | US | disclosed |
| CN-1370154-A | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI SYNTHELABO (FR) | 2002-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | CRH, CRHR1, CRHR2 | SLC6A4 175/4885SLC6A2 232/4885SLC6A3 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.